Emergence of Mupirocin-Resistant Staphylococcus Aureus in Chronic Peritoneal Dialysis Patients using Mupirocin Prophylaxis to Prevent Exit-Site Infection
Restricted accessResearch articleFirst published online November, 2001
Emergence of Mupirocin-Resistant Staphylococcus Aureus in Chronic Peritoneal Dialysis Patients using Mupirocin Prophylaxis to Prevent Exit-Site Infection
To determine the prevalence of the carriage of Staphylococcus aureus (SA), methicillin-resistant Staphylococcus aureus (MRSA), and mupirocin-resistant Staphylococcus aureus (MuRSA) in chronic peritoneal dialysis (CPD) patients after 4 years of prophylactic mupirocin application to the exit site, in a peritoneal dialysis unit.
Methods
Three swabs were collected from the nares, axillae/groin, and exit site, respectively, from 149 patients on CPD between May and July 2001. All swabs were cultured on solid selective agar (mannitol salt agar) and in mannitol salt broth. Staphylococcus aureus isolates were tested for methicillin resistance using oxacillin screening plates, and mupirocin resistance using E-test strips. Low-level MuRSA was defined as minimum inhibitory concentration (MIC) of 4 mg/mL or more, and high-level MuRSA as MIC of 256 mg/mL or more.
Results
Staphylococcus aureus was isolated from 26 (17%) patients (25 from nares/axilla/groin, and 1 from the exit site). High-level MuRSA was isolated from 4 patients (3% of the total study population; 15% of total SA isolates). No MRSA was detected. One patient with high-level MuRSA had peritonitis due to SA, resulting in treatment failure and catheter loss, soon after the swabs were collected for the study.
Conclusion
We report the emergence of high-level MuRSA in CPD patients after a 4-year practice of continuous use of mupirocin in a small number of patients in our unit. Our results may have significant implications for the future practice of prophylactic use of mupirocin by CPD patients to prevent exit-site infection.
PirainoB.Staphylococcus aureus infections in dialysis patients: focus on prevention.ASAIO J2000; 6(6): S13–7.
2.
LuzarM.A., ColesG.A., FallerB., SlingeneyerA., DahG.D., BriatC.Staphylococcus aureus carriage and infections in patients on continuous ambulatory dialysis.N Engl J Med1990; 322: 505–9.
3.
Mupirocin Study Group.Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis.J Am Soc Nephrol1996; 7: 2403–8.
4.
ZimmermanS.W., AhrensE., JohnsonC.A., CraigW., LeggettJ., O'BrienM.Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections.Am J Kidney Dis1991; 18: 225–31.
5.
ThodisE., BhaskaranS., PasadakisP., BargmanJ.M., VasS.I., OreopoulosD.G.Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.Perit Dial Int1998; 18: 261–70.
6.
BernardiniJ., PirainoB., HolleyJ., JohnsonJ.R., LutesR.A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.Am J Kidney Dis1996; 27: 695–700.
7.
CaseyM., TaylorJ., ClinardP., GrahamV., MauckL., SpainhourP.Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients.Perit Dial Int2000; 20: 566–8.
8.
AmatoD., VenturaM.J., MirandaG., LeanosB., AlcantaraG., HurtadoM.E.Staphylococcal peritonitis in continuous ambulatory peritoneal dialysis: Colonization with identical strains at exit site, nose and hands.Am J Kidney Dis2001; 37: 43–8.
VasquezJ.E., WalkerE.S., FranzusM.S., OverbayB.K., ReaganD.R., SarubbiF.A.The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans’ Affairs Hospital.Infect Control Hosp Epidemiol2000; 21: 459–64.
11.
SchmitzF.J., LindenlaufE., HofmannB., FluitA.C., VerhoefJ., HeinzH.P.The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals.J Antimicrob Chemother1998; 42: 489–95.
12.
Dos SantosK.R.N., de Souza FonsecaL., FilhoP.P.G.Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals.Infect Control Hosp Epidemiol1996; 17: 813–16.
13.
MillerM.A., DascalA., PortnoyJ., MendelsonJ.Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment.Infect Control Hosp Epidemiol1996; 17: 811–13.
14.
MatanabeH., MasakiH., AsohN., WatanabeK., OishiK., FurumotoA.Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan.J Hosp Infect2001; 47: 294–300.
15.
VasS.I., ConlyJ., BargmanJ.M., OreopoulosD.G.Resistance to mupirocin: No indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients.Perit Dial Int1999; 19: 313–14.
16.
RosalesM., Pérez–FontánM., Rodríguez–CarmonaA., García–FalcónT.Increasing resistance to mupirocin of Staphylococcus aureus (S Au) strains isolated from peritoneal dialysis (PD) patients and their partners: long term study (Abstract).Perit Dial Int2001; 21(Suppl 2): S128.
17.
FuchsP.C., JonesR.N., BarryA.L.Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic.J Clin Microbiol1990; 28: 608–9.
18.
PolepouM.F., JohnsonA.P., CooksonB.D., BeattieH., CharlettA., WoodfordN.Evaluation of disc diffusion and E test for determining the susceptibility of Staphylococcus aureus to mupirocin.J Antimicrob Chemother1998; 42: 577–83.
19.
CooksonB.D.The emergence of mupirocin resistance: A challenge to infection control and antibiotic prescribing practice.J Antimicrob Chemother1998; 41: 11–18.
20.
CooksonB.D.Antiseptic resistance in methicillin-resistant Staphylococcus aureus: an emerging problem.Int J Med Microbiol1994; Suppl 26: 227–34.
ReadheadR.J., LambR.J., RowsellR.B.The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage.Br J Clin Pract1991; 45: 252–4.
26.
BastosM.C., MondinoP.J., AzevedoM.L., SantosK.R., Giambiagi–deMarvalM.Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin.Eur J Clin Microbiol Infect Dis1999; 18: 393–8.
27.
DaviesS.J., OggC.S., CameronJ.S., PostonS., NobleW.C.Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD).Perit Dial Int1989; 9: 61–4.
28.
HanslikT.M., NewmanL., TessmanM., MorrisseyA.B., FriedlanderM.A.Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site infections: results unaffected by routine mupirocin treatment of nasal S. aureus carriage.Adv Perit Dial1994; 10: 158–62.
29.
Perez-FontanM., RosalesM., Rodriguez-CarmonaA., MoncalianJ., Fernandez-RiveraC., CaoM.Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin.Adv Perit Dial1992; 8: 242–5.
30.
ZimakoffJ., Bangsgaard PedersenF., BergenL., Baago–NeilsenJ., DaldorphB., EspersenF.Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centers in Denmark.J Hosp Infect1996; 33: 289–300.
31.
VychytilA., LorenzM., SchneiderB., HoriW.H., Haag–WeberM.New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients.J Am Soc Nephrol1998; 9: 669–76.
32.
TurnerK., UttleyL., ScrimgeourA., McKewanA., GokalR.Natural history of Staphylococcus aureus nasal carriage and its relation to exit-site infection.Perit Dial Int1998; 18: 271–3.
33.
FungS., O'GradyS., KennedyC., DedierH., CampbellI., ConlyJ.The utility of polysporin ointment in the eradication of methicillin-resistant Staphylococcus aureus colonization: a pilot study.Infect Control Hosp Epidemiol2000; 21: 653–5.
34.
CarsonC.F., CooksonB.D., FarrellyH.D., RileyT.V.Susceptibility of methicillin-resistant Staphylococcus aureus to the essential oil of Melaleuca alternifolia.J Antimicrob Chemother1995; 35: 421–4.
35.
HillR.L., CasewellM.W.The in-vitro activity of povidone-iodine cream against Staphylococcus aureus and its bioavailability in nasal secretions.J Hosp Infect2000; 45: 198–205.
36.
MapleP.A., Hamilton–MillerJ.M., BrumfittW.Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against Staphylococcus aureus.J Antimicrob Chemother1992; 29: 661–8.
37.
IrishD., EltringhamI., TeallA., PickettH., FarellyH., ReithS.Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin.J Hosp Infect1998; 39: 19–26.
38.
DaveyP., CraigA.M., HauC., MalekM.Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial.J Antimicrob Chemother1999; 43: 105–12.
